Owens & Minor, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US6907321029
USD
2.55
-0.05 (-1.92%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Owens & Minor, Inc. stock-summary
stock-summary
Owens & Minor, Inc.
Pharmaceuticals & Biotechnology
Owens & Minor, Inc. is a healthcare solutions company with integrated technologies, products and services. The Company operates through two segments: Global Solutions and Global Products. Global Solutions segment includes its United States distribution, outsourced logistics and value-added services business. Global Products manufactures and sources medical surgical products through its production and kitting operations. Global Solutions segment offers a portfolio of products and services to healthcare providers and manufacturers. Its portfolio of medical and surgical supplies includes products purchased from manufacturers and its own proprietary products. Global Products segment provides medical supplies and solutions for the prevention of healthcare-associated infections across the acute and alternate site channels. Its manufacturing facilities are located in the United States, Thailand, Honduras, Mexico and Ireland.
Company Coordinates stock-summary
Company Details
9120 LOCKWOOD BLVD , MECHANICSVILLE VA : 23116
stock-summary
Tel: 1 804 72370001 804 7237556
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 75 Schemes (63.96%)

Foreign Institutions

Held by 114 Foreign Institutions (8.42%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Robert Sledd
Independent Chairman of the Board
Mr. Edward Pesicka
President, Chief Executive Officer, Director
Mr. Mark Beck
Independent Director
Lt. Gen. Gwendolyn Bingham
Independent Director
Mr. Robert Henkel
Independent Director
Mr. Mark McGettrick
Independent Director
Mr. Eddie Moore
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
682 Million
(Quarterly Results - Jun 2025)
Net Profit:
-84 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 416 Million (Micro Cap)

stock-summary
P/E

6.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-7.06

stock-summary
Return on Equity

-76.43%

stock-summary
Price to Book

-1.48